Following an AIS, BBB impairment allows inflammatory cells to infiltrate the brain parenchyma, where released cytokines (TNF-α, IL-1 β, IL-6) can exacerbate brain tissue damage, thereby increasing the risk of HT. The gene discussed is IL6; the disease is hematocrit.